Literature DB >> 332358

Pathology of the non-Hodgkin's lymphomas: new classifications.

R F Dorfman.   

Abstract

This paper briefly reviews the various classifications proposed as alternatives to that of Rappaport. Rappaport's classification is valuable because it is applicable to clinicopathologic studies, but there are areas of contention. Following the Airlie Conference, which failed to resolve the current controversy about classification, the National Cancer Institute proposed to support a retrospective study of 1000 cases of non-Hodgkin's lymphoma, during which the various classifications will be applied to the biopsy slides by a selected panel of pathologists. It is hoped that this study will meet the urgent need for a classification which will eliminate controversial terminology and will employ terms acceptable to pathologists in their daily diagnostic work and to hematologists and oncologists burdened with the choice of therapy for patients affected by the non-Hodgkin's lymphomas.

Entities:  

Mesh:

Year:  1977        PMID: 332358

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  5 in total

1.  Morphology of lymphatic cells and of their derived tumours.

Authors:  F Rilke; S Pilotti; A Carbone; L Lombardi
Journal:  J Clin Pathol       Date:  1978-11       Impact factor: 3.411

2.  Primary intestinal lymphomas.

Authors:  H F Otto; I Bettmann; J V Weltzien; J O Gebbers
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1981

3.  Malignant lymphoma in the residual stomach after gastrectomy. A case report.

Authors:  T Sudo; S Shiraha; K Ishiyama; M Kawamura; M Takemoto; H Umemura; T Kuyama; S Hashimoto
Journal:  Jpn J Surg       Date:  1982

4.  Primary gastric lymphoma. A review of 50 cases.

Authors:  B Dworkin; C J Lightdale; D N Weingrad; J J DeCosse; P Lieberman; D A Filippa; P Sherlock; D Straus
Journal:  Dig Dis Sci       Date:  1982-11       Impact factor: 3.199

5.  A unique cell surface antigen identifying lymphoid malignancies of B cell origin.

Authors:  L M Nadler; J Ritz; R Hardy; J M Pesando; S F Schlossman; P Stashenko
Journal:  J Clin Invest       Date:  1981-01       Impact factor: 14.808

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.